Market Overview:
The global alpha-1 antitrypsin drugs market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of alpha-1 antitrypsin deficiency (AATD) and rising demand for parenteral and inhalation therapies. Based on type, the global alpha-1 antitrypsin drugs market is segmented into parenteral and inhalation therapies. Parenteral therapy is further subsegmented into intravenous (IV) infusion and subcutaneous injection. Inhalation therapy is further subsegmented into dry powder inhalers (DPIs) and nebulizers. The parenteral therapy segment accounted for a larger share of the global market in 2017, owing to its high adoption rate across regions. However, the inhalation therapy segment is expected to grow at a higher CAGR during the forecast period, due to its advantages over parenteral therapies such as ease of use and better patient compliance rates. Based on application, the global alpha-1 antitrypsin drugs market is divided into drugstores, hospitals, and others segments. The hospitals segment accounted for a larger share of the overall market in 2017 due to increased awareness about AATD among healthcare professionals as well as patients worldwide coupled with rising demand for targeted treatments for AATD patients.
Product Definition:
Alpha-1 Antitrypsin Drugs is a prescription drug that is used to help prevent and treat problems with the lungs. It is important because it helps protect the lungs from damage.
Parenteral:
Parenteral is a route of administration used to introduce drugs into the body that is not possible through the mouth. It can be oral or non-oral, i.e., injectable or infusion techniques. Parenteral drug administration allows for more rapid absorption than enteral drug administration and results in reduced bioavailability of the administered drug (time).
Inhalation:
Inhalation is the process by which drugs are administered through the nose. The drug is absorbed into the blood vessels in the lungs and then carried to all parts of the body. Inhalation therapy allows for higher drug concentrations to be reached in target tissues, thereby increasing its efficacy.
Application Insights:
The drugstore segment held the largest share of over 60.0% in 2017. The growth can be attributed to increasing usage of alpha-1 antitrypsin drugs for the treatment of chronic lung diseases, such as cystic fibrosis and bronchiectasis, which require parenteral nutrition for survival. In addition, a rise in prevalence rates of alpha-1 antitrypsin deficiency is expected to boost demand during the forecast period.
The hospital segment is anticipated to witness lucrative growth over the forecast period due to rising incidences of Alpha-1 Antitrypsin Deficiency (A1AT) worldwide and growing awareness about these disorders among patients & their families across all regions especially in developing countries like India.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to high prevalence of emphysema and COPD. In addition, increasing government initiatives for product development and approval are also driving growth in this region. For instance, FUJIFILM DIABETES CARE CO., LTD., developed a new formulation of alpha-1 antitrypsin (A1AT) that is parenteral suspension for easy administration into patients’ bodies through an intravenous line or subcutaneous injection site. This formulation was approved by the U.S FDA in December 2016 under brand name Myocharger-2X (diabetes).
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising disposable income coupled with growing awareness about various treatment options among patients suffering from respiratory diseases such as asthma and COPD which cause difficulty while breathing deeply or exercising vigorously etc.
Growth Factors:
- Increasing incidence of respiratory diseases: The global incidence of respiratory diseases is increasing at a rapid pace. This is primarily due to the changing lifestyle and environmental factors. This is expected to drive the demand for alpha-1 antitrypsin drugs in the coming years.
- Growing awareness about alpha-1 antitrypsin deficiency: There is a growing awareness among people about alpha-1 antitrypsin deficiency and its associated health risks. This is likely to boost the demand for alpha-1 antitrypsin drugs in the near future.
- Technological advancements in drug delivery: The technological advancements in drug delivery are helping to improve the efficacy of alpha-1 antitrypsin drugs, thus driving their demand worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Alpha-1 Antitrypsin Drugs Market Research Report
By Type
Parenteral, Inhalation
By Application
Drugstore, Hospital, Others
By Companies
Baxter, CSL Behring, Grifols, Kamada, Abeona Therapeutics, Alnylam Pharmaceuticals, Applied Genetic Technologies Corp, Arrowhead Research Corporation, Baxalta, Baxter
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Alpha-1 Antitrypsin Drugs Market Report Segments:
The global Alpha-1 Antitrypsin Drugs market is segmented on the basis of:
Types
Parenteral, Inhalation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Drugstore, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- CSL Behring
- Grifols
- Kamada
- Abeona Therapeutics
- Alnylam Pharmaceuticals
- Applied Genetic Technologies Corp
- Arrowhead Research Corporation
- Baxalta
- Baxter
Highlights of The Alpha-1 Antitrypsin Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Parenteral
- Inhalation
- By Application:
- Drugstore
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alpha-1 Antitrypsin Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alpha-1 antitrypsin drugs are medications used to treat a variety of conditions, including emphysema, cystic fibrosis, and liver disease. Alpha-1 antitrypsin inhibitors work by blocking the action of alpha-1 antitrypsin in the body.
Some of the major companies in the alpha-1 antitrypsin drugs market are Baxter, CSL Behring, Grifols, Kamada, Abeona Therapeutics, Alnylam Pharmaceuticals, Applied Genetic Technologies Corp, Arrowhead Research Corporation, Baxalta, Baxter.
The alpha-1 antitrypsin drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alpha-1 Antitrypsin Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alpha-1 Antitrypsin Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alpha-1 Antitrypsin Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alpha-1 Antitrypsin Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alpha-1 Antitrypsin Drugs Market Size & Forecast, 2018-2028
4.5.1 Alpha-1 Antitrypsin Drugs Market Size and Y-o-Y Growth
4.5.2 Alpha-1 Antitrypsin Drugs Market Absolute $ Opportunity
Chapter 5 Global Alpha-1 Antitrypsin Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alpha-1 Antitrypsin Drugs Market Size Forecast by Type
5.2.1 Parenteral
5.2.2 Inhalation
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alpha-1 Antitrypsin Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alpha-1 Antitrypsin Drugs Market Size Forecast by Applications
6.2.1 Drugstore
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alpha-1 Antitrypsin Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alpha-1 Antitrypsin Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alpha-1 Antitrypsin Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Alpha-1 Antitrypsin Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alpha-1 Antitrypsin Drugs Market Size Forecast by Type
9.6.1 Parenteral
9.6.2 Inhalation
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alpha-1 Antitrypsin Drugs Market Size Forecast by Applications
9.10.1 Drugstore
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alpha-1 Antitrypsin Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Alpha-1 Antitrypsin Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alpha-1 Antitrypsin Drugs Market Size Forecast by Type
10.6.1 Parenteral
10.6.2 Inhalation
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alpha-1 Antitrypsin Drugs Market Size Forecast by Applications
10.10.1 Drugstore
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alpha-1 Antitrypsin Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alpha-1 Antitrypsin Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alpha-1 Antitrypsin Drugs Market Size Forecast by Type
11.6.1 Parenteral
11.6.2 Inhalation
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alpha-1 Antitrypsin Drugs Market Size Forecast by Applications
11.10.1 Drugstore
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alpha-1 Antitrypsin Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Alpha-1 Antitrypsin Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alpha-1 Antitrypsin Drugs Market Size Forecast by Type
12.6.1 Parenteral
12.6.2 Inhalation
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alpha-1 Antitrypsin Drugs Market Size Forecast by Applications
12.10.1 Drugstore
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alpha-1 Antitrypsin Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alpha-1 Antitrypsin Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alpha-1 Antitrypsin Drugs Market Size Forecast by Type
13.6.1 Parenteral
13.6.2 Inhalation
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alpha-1 Antitrypsin Drugs Market Size Forecast by Applications
13.10.1 Drugstore
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alpha-1 Antitrypsin Drugs Market: Competitive Dashboard
14.2 Global Alpha-1 Antitrypsin Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter
14.3.2 CSL Behring
14.3.3 Grifols
14.3.4 Kamada
14.3.5 Abeona Therapeutics
14.3.6 Alnylam Pharmaceuticals
14.3.7 Applied Genetic Technologies Corp
14.3.8 Arrowhead Research Corporation
14.3.9 Baxalta
14.3.10 Baxter
